That's a good question.
Your reasoning makes sense, but there are several factors that influence the development and commercialisation of new technologies, such as the sequence of optimizing MOCVD devices before introducing a new RPCVD "dual n wave" device with a tunnel junction. There are a few considerations to bear in mind:
Technology Development and Maturation: Developing a new technology, such as RPCVD for tunnel junctions, involves a significant amount of research, development, and optimization. It's important to establish the basic principles, understand the materials and processes, and ensure that the technology is reliable and reproducible. MOCVD technology has already been extensively researched and optimized, so manufacturers might start with optimizing that technology before moving on to newer techniques like RPCVD.
Market Acceptance and Validation: Before introducing a new technology to the market, manufacturers often want to ensure that it is well-validated and meets the performance and reliability standards that customers expect. Launching a completely new technology like RPCVD with a "dual n wave" device might require additional validation and testing to demonstrate its capabilities and reliability, especially if it's intended for critical applications like lasers.
Incremental Improvements: The development of a technology roadmap often involves incremental improvements. By first optimizing the efficiency of MOCVD devices, manufacturers can offer better performance to their customers while continuing research and development on newer technologies like RPCVD. This approach allows for a smoother transition and minimizes disruption to the market.
Risk Management: Introducing a new technology always carries some level of risk. By first optimizing MOCVD devices, manufacturers can continue to serve their existing customer base while they work on validating and refining the new RPCVD technology. This approach helps manage potential risks associated with the adoption of a new and unproven technology.
Innovation and technological advancement often follow a strategic and stepwise approach to balance the benefits of new capabilities with the challenges of technology development, validation, and market adoption. While it might seem logical to leapfrog to a new technology, there are practical considerations and risks that manufacturers take into account when deciding on their development and commercialization strategies.
- Forums
- ASX - By Stock
- Ann: BluGlass to host virtual shareholder session
BLG
bluglass limited
Add to My Watchlist
0.00%
!
0.9¢

That's a good question.Your reasoning makes sense, but there are...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.71M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.9¢ | $104.2K | 11.52M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
33 | 13241597 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 14726803 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
33 | 13241597 | 0.008 |
16 | 12894473 | 0.007 |
4 | 8534000 | 0.006 |
4 | 5700000 | 0.005 |
1 | 1000000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 14726803 | 14 |
0.011 | 5092560 | 9 |
0.012 | 2660979 | 7 |
0.013 | 2213100 | 5 |
0.014 | 2550000 | 3 |
Last trade - 15.47pm 26/06/2025 (20 minute delay) ? |
Featured News
BLG (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online